Ensoma has emerged with $70m in series A financing to advance research from Fred Hutchinson and University of Washington.

US-based genomic medicine developer Ensoma launched on Thursday with $70m in series A financing to commercialise research from University of Washington and Fred Hutchinson Cancer Research Center.
5AM Ventures led the round, which also included financial services group Fidelity’s F-Prime Capital unit, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners and Symbiosis II.
Life sciences real estate investment trust Alexandria Real Estate Equities and pharmaceutical firm Takeda invested through Alexandria Venture Investments and Takeda Ventures, respectively, with…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).